Page last updated: 2024-11-04

sb 202190 and Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

sb 202190 has been researched along with Precursor B-Cell Lymphoblastic Leukemia-Lymphoma in 1 studies

4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma: A leukemia/lymphoma found predominately in children and adolescents and characterized by a high number of lymphoblasts and solid tumor lesions. Frequent sites involve LYMPH NODES, skin, and bones. It most commonly presents as leukemia.

Research Excerpts

ExcerptRelevanceReference
"Acute lymphoblastic leukemia (ALL) is the most common hematological malignancy affecting children."1.34Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy. ( Barredo, JC; Hsieh-Kinser, TT; Leclerc, GJ; Leclerc, GM; Sengupta, TK; Singh, I, 2007)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Sengupta, TK1
Leclerc, GM1
Hsieh-Kinser, TT1
Leclerc, GJ1
Singh, I1
Barredo, JC1

Other Studies

1 other study available for sb 202190 and Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

ArticleYear
Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy.
    Molecular cancer, 2007, Jul-10, Volume: 6

    Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Cell Di

2007